Skip to the page

Data / Drug companies / Granules USA, Inc.

Granules USA, Inc.: 14 products in the FDA NDC directory, labeler code 69848

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Granules USA, Inc. (labeler code 69848) lists 14 products in the FDA National Drug Code Directory, covering 10 finished drugs by generic name. By type: 14 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on December 10, 2024.

The request: Watch Granules USA, Inc. (FDA labeler code 69848): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
69848
Products in commercial distribution
14
Packages
23
Finished drugs by generic name
10
Prescription products
0
Over the counter products
14
Flagged as original packager
14 of 14 products that carry the flag
Started marketing in the last 12 months
0
Earliest marketing start
July 1, 2018
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Generic drugs (ANDA)964.3%
Over the counter monograph drugs535.7%

Products by type

TypeProductsShare
Over the counter drugs14100%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

Dosage forms

Dosage formProductsShare
Tablet964.3%
Tablet, extended release214.3%
Capsule, liquid filled17.1%
Tablet, film coated, extended release17.1%
Solution17.1%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Aacetaminophen and Ibuprofen69848-588TabletGeneric drugs (ANDA)December 10, 2024
Guaifenesin69848-018Tablet, extended releaseGeneric drugs (ANDA)September 12, 2024
Guaifenesin69848-017Tablet, extended releaseGeneric drugs (ANDA)December 31, 2021
Loratadine69848-019TabletGeneric drugs (ANDA)July 26, 2021
Cetirizine Hydrochloride69848-006TabletGeneric drugs (ANDA)June 30, 2021
Sennosides69848-016Capsule, liquid filledOver the counter monograph drugsMay 29, 2020
Acetaminophen69848-008TabletOver the counter monograph drugsMay 1, 2020
Acetaminophen69848-015Tablet, film coated, extended releaseGeneric drugs (ANDA)December 31, 2019
Acetaminophen Diphenhydramine HCl69848-014TabletOver the counter monograph drugsJuly 1, 2019
Ibuprofen69848-012TabletGeneric drugs (ANDA)July 1, 2019
Ibuprofen69848-011TabletGeneric drugs (ANDA)July 1, 2019
Naproxen Sodium69848-010TabletGeneric drugs (ANDA)July 1, 2019
Acetaminophen69848-003TabletOver the counter monograph drugsJuly 1, 2019
Clotrimazole69848-001SolutionOver the counter monograph drugsJuly 1, 2018

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.